IDH1 and acute myeloid leukemia: Results from a phase IB/II study of ivosidenib with AZA and venetoclax that included 25 patients with MDS and newly diagnosed or relapsed/refractory AML with IDH1 mutations showed an ORR of 92% and a composite CR rate of 84% [90].